Suppression of Luteinizing Hormone Enhances HSC Recovery after Hematopoietic Injuries

Enrico Velardi(Bambino Gesù Children's Hospital), Marcel R.M. van den Brink(City Of Hope National Medical Center), Robert R. Jenq(City Of Hope National Medical Center), Jennifer J. Tsai(Memorial Sloan Kettering Cancer Center), Stefan Radtke(Fred Hutch Cancer Center), Kirsten Cooper(Fred Hutch Cancer Center), Hans‐Peter Kiem(Fred Hutch Cancer Center), Jae-Hung Shieh(Cornell University), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Alan M. Hanash(Memorial Sloan Kettering Cancer Center), M A Moore, Jarrod A. Dudakov(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Transplantation and Cellular Therapy
February 3, 2018
10.1016/j.bbmt.2017.12.688
Cited by 0

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration
|Nature|2015|1.1k
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937